Concepedia

Publication | Open Access

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma

DOIFull Paper Access

53

Citations

20

References

2021

Year

Jennifer E. Amengual, Jennifer Kimberly Lue, Helen Ma, Renee Lichtenstein, Bijal Shah, Serge Cremers, Simon Jones, Ahmed Sawas
The Oncologist

Abstract

ACY-1215 is an oral selective HDAC6 inhibitor that was safe in patients with relapsed and refractory lymphoid malignancies and led to disease stabilization in half of the evaluable patients.

References

YearCitations

Page 1